Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

Transcenta rounds out year with $105M crossover round
Transcenta Holding Ltd. raises $105 million in a crossover round led by China Structural Reform Fund. New investors Country Garden Venture Capital, Qatar Investment Authority, and existing investors CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, and Sequoia Capital China were among the firms participating in this round. The global biologics company, which is led by co-founder and CEO Xueming Qian, has now raised more than $347 million.

Junshi leads Risen’s $61M round
Risen (Shanghai) Medical Technology Co. Ltd. raised nearly RMB400 million ($61.1 million) in a series B round led by Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) with participation by Swiss China and a fund affiliated with Xiaoxiang Capital. Risen is developing small molecules for bone and neurodegenerative diseases, cancer and drug-resistant infections...